S. PETER LUDWIG has a broad range of experience in complex domestic and foreign patent prosecution, litigation, interference and counseling issues, particularly in representing high-tech start-up companies. His technical expertise includes biotechnology (vaccines, functional genomics, pharmacogenomics, high throughput screening, stem cell technology, autoimmune diseases, gene therapy), pharmaceuticals (neuroleptic drugs, drug delivery systems, anti-metabolites, natural pharmaceuticals, anti-tumor agents, anti-viral agents), medical devices, photo-chemistry, paper chemistry, medical rubber products, aluminum processing and diagnostic products.
Mr. Ludwig, who began his career as a patent attorney for E.I. DuPont de Nemours, has been involved in all phases of intellectual property litigation, from discovery through trial. His notable cases include Vilcek v. Enzo Biochem Inc., an arbitration proceeding, involving the cloning of gamma-interferon; Westvaco v. International Paper Company (991 F.2d 735); Fromson v. Anitec (132 F.3d 1437); and Allegiance Healthcare v. SSL (70 U.S.P.Q. 2d 1286).
Mr. Ludwig has spoken on intellectual property issues for numerous professional associations, including the American Chemical Society, Pharmaceutical Research and Manufacturers of America, the Biotechnology Industry Association and the New York Intellectual Property Law Association.
Under an Ampart grant from the United States State Department, Mr. Ludwig lectured and advised government authorities and industry representatives in Brazil on strengthening intellectual property rights for biotechnology and pharmaceuticals.
Since 2001, Mr. Ludwig has served as a speaker and as the chair of the annual Biotechnology and Pharmaceutical Law and Business Program sponsored by the Practising Law Institute in New York and San Francisco.